RKRathana Kim

Rathana Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rathana Kim has a total of 526 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi‐LMC study

    by Benjamin Podvin, Olivier Nibourel, Sandrine Hayette, Valérie Coiteux, Rathana Kim, Lucie Rigolot, Stéphanie Dulucq, Augustin Boudry, Geoffrey Pawlak, Wayne-Corentin Lambert, et al.

    The rarer p190 (e1a2) transcript in chronic myeloid leukemia (CML) is associated with atypical presentations; yet, its biological basis remains poorly understood. Using a cohort of 60 patients including 42 chronic phase patients age‐matched 1:1 with 42 e13a2/e14a2 patients in the chronic phase, we investigated the clinical, genomic, and clonal features of e1a2 BCR::ABL1 CML. We identified 60 e1a2 BCR::ABL1 CML patients showing distinctive hematologic features including lower leukocyte and platelet counts and higher monocytosis (12.3% vs. 2.0%, P < 0.001). Additional somatic mutations were detected in 37/42 (88%) e1a2 BCR::ABL1 cases compared with 7/42 (17%) e13a2/e14a2 BCR::ABL1 cases. The mutational spectrum was dominated by ASXL1 and TET2 , and closely resembled CMML‐like profiles. Genomic breakpoint sequences of 34 e1a2 BCR::ABL1 cases showed that BCR and ABL1 coordinates were similar to those observed in 394 B‐ALL. Longitudinal mutational tracking revealed two distinct clonal architectures. In 71% of patients, mutations disappeared with molecular response, consistent with BCR::ABL1 as the founding event. In contrast, 29% of patients had mutations with stable VAFs, while BCR::ABL1 transcript levels decreased after treatment, indicating that the fusion had been acquired within a pre‐existing mutated clone. Single‐cell genotyping experiments confirmed these clonal architectures. These patients frequently developed cytopenias under tyrosine kinase inhibitor therapy and half required red blood cell transfusions, reflecting persistence of the ancestral clone rather than BCR::ABL1 ‐driven disease. These findings show that e1a2 BCR::ABL1 CML frequently arises within complex, premutated clonal backgrounds, providing a biological basis for its atypical presentation and heterogeneous treatment response.

  • Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia

    by Camille Vaganay, Frank Ling, Lois M. Kelly, Juliette Charles, Paul-Arthur Meslin, Hélène Pasquer, Rathana Kim, Marie Passet, Matthieu Duchmann, Léa Pelissier-Menjaud, et al.

    Chemotherapy resistance in acute myeloid leukemia (AML) remains a major clinical challenge. Integration of multiomic profiling and in vivo functional genomics revealed splicing dysregulation as a determinant of chemoresistance in AML. We uncovered a network involving the splicing regulator SRRM1 and the CLK1/4 and PAK1 kinase families as vulnerabilities in chemoresistant AML cells. Both kinase families are hyperactivated in chemoresistant cells, promoting SRRM1 phosphorylation and altering its scaffolding function. We also identified a relapse-associated PAK1 variant, c.1429G>T p.(Ala 477 →Ser), that confers chemotherapy resistance. Combined PAK1 and CLK1/4 inhibition recapitulated the splicing changes induced by SRRM1 loss, preferentially targeting chemoresistant AML and enhancing chemotherapy efficacy in cell lines, primary cells, and mouse models. Last, we pinpointed MAP2K5 as a critical downstream effector because missplicing of exons 17 and 18 of MAP2K5 upon SRRM1 depletion sensitized cells to chemotherapy. Our findings highlight a therapeutic strategy to overcome AML relapse by targeting splicing dysregulation.

  • Open Access

    CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemia

    by Rathana Kim, Marie Passet, Hugo Bergugnat, Loïc Vasseur, Thibaut Leguay, Françoise Huguet, Mathilde Hunault, Tom Sexton, Melha Benlebna, Julie Renard, et al.

    B‐cell acute lymphoblastic leukemia (B‐ALL) is a heterogeneous malignancy driven by diverse genetic alterations. Among these, CEBP family genes and ZEB2 are recurrently involved, yet the spectrum of genomic mechanisms and their clinical impact remain incompletely defined. Integrated genomic analyses of a cohort of 992 Philadelphia‐negative adult B‐ALL patients revealed multiple mechanisms of enhancer hijacking‐mediated deregulation of CEBPA , CEBPB , CEBPD , and CEBPE , including IGH and several non‐ IGH fusions, as well as noncoding mutations in regulatory regions. Combined with gene expression analysis, we identified three distinct subtypes, defined by co‐occurring CEBP and ZEB2 p.H1038R alterations (CEBP/ZEB2, n = 18 cases); isolated CEBP alterations (CEBPalt, n = 43), associated with frequent IKZF1 deletions and FLT3 deregulation; and isolated ZEB2 p.H1038R mutation (ZEB2alt, n = 15), associated with various additional genomic hits targeting ZEB2 and enhancing mutant ZEB2 expression. The three subtypes exhibited distinct clinical features, including age distribution (patients with CEBP/ZEB2 and ZEB2alt B‐ALL were younger) and sex bias (female and male predominance in CEBPalt and ZEB2alt, respectively). Early treatment responses and outcomes also differed: patients with CEBP/ZEB2 B‐ALL had a favorable early response, in contrast to patients with ZEB2alt B‐ALL, who had high levels of minimal residual disease and a dismal prognosis. Collectively, our findings define CEBP and ZEB2 alterations as drivers of genetically and clinically distinct subtypes of adult B‐ALL and provide a rationale for subtype‐specific risk stratification. Preclinical experiments in CEBPalt B‐ALL patient‐derived xenografts demonstrated sensitivity to FLT3 inhibition, highlighting a potential therapeutic vulnerability.


  • Open Access

    Persistent BCR::ABL1 ‐positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome‐positive ALL

    by Jean‐Edouard Martin, Julien Cliquot, Rathana Kim, Stéphanie Mathis, Jean‐Michel Cayuela, Marie Passet, Baptiste Gaillard, Chantal Himberlin, André Baruchel, Raphaël Itzykson, et al.

  • Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study

    by Nicolas Boissel, Françoise Huguet, Thibaut Tl Leguay, Mathilde Hunault, Rathana Kim, Yosr Hicheri, Marie Passet, Patrice Chevallier, Marie Balsat, Cedric Pastoret, et al.

    Intensified chemotherapy regimens have improved outcomes in adults with Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL), yet relapse remains a major cause of treatment failure and death. Blinatumomab, a CD19×CD3 bispecific T-cell engager, has demonstrated marked activity in relapsed, measurable residual disease (MRD)-positive B-ALL, and in frontline consolidation for MRD-negative patients. The phase 2 GRAALL-2014/B-QUEST sub-study (NCT02617004) evaluated the integration of blinatumomab into consolidation and maintenance therapy for adults with high-risk (HR) B-ALL treated within the GRAALL-2014/B trial. Between 2015 and 2020, 489 adults aged 18-59 years with newly diagnosed Ph-negative B-ALL were enrolled, among them 259 were classified as HR (presence of KMT2A-r, IKZF1 deletion, or end-of-induction MRD≥10-4). Ninety-four HR patients enrolled in QUEST (2018-2020) received up to five 28-day cycles of blinatumomab integrated into consolidation and maintenance. Ninety HR patients treated before QUEST activation without blinatumomab served as controls in a post hoc analysis. Baseline characteristics were comparable. Blinatumomab consolidation significantly improved MRD clearance, reduced relapse, and prolonged survival. At 5 years, cumulative incidence of relapse, disease-free survival (DFS), and overall survival were 23%, 68%, and 79% versus 49% (p=0.001), 42% (p=0.001), and 60% (p=0.03) in controls. Outcome benefit generally favored blinatumomab across subgroups, although not reaching significance in KMT2A-rearranged cases. Very high-risk patients eligible for alloHSCT derived overall benefit. However, no clear additional DFS advantage was observed among those ultimately transplanted. These findings support frontline integration of blinatumomab and warrant prospective evaluation of transplantation strategies in this setting.


  • Ontogénie des leucémies aiguës lymphoblastiques B de l'adulte : caractérisation de la cellule d'origine et implication d'une hématopoïèse clonale

    by Rathana Kim

    La leucémie aiguë lymphoblastique B (LAL-B) représente le cancer le plus fréquent chez l'enfant bien que pouvant survenir à tout âge. Elle représente un modèle d'oncogenèse bien caractérisé et un paradigme de succès thérapeutique basé sur une optimisation progressive du traitement couplée à une stratification basée sur des facteurs pronostiques. Cependant, alors que le taux de guérison dépasse 90% chez l'enfant, son pronostic reste réservé chez l'adulte. Ce contraste s'explique en partie par la toxicité des traitements et les comorbidités qui augmentent avec l'âge. Une autre cause, complémentaire, tenant à la nature de la leucémie elle-même, nous a amené à formuler l'hypothèse de travail selon laquelle l'ontogénie des LAL-B de l'adulte se distinguerait de celle de l'enfant et déterminerait des caractéristiques génétiques, cliniques et pronostiques différentes. Nous avons centré notre étude sur les 3 entités de LAL-B les plus fréquentes chez l'adulte, définies par la présence d'un chromosome de Philadelphie (Ph+), d'une hypodiploïdie sévère (HoTr) ou d'un réarrangement de KMT2A (KMT2A-r). L'objectif de ce travail était de mieux comprendre la biologie de ces leucémies, leur lien avec le vieillissement et la réponse au traitement. Une attention particulière a été portée à la question de la cellule d'origine, aux altérations génomiques associées et à l'architecture clonale. Dans les LAL Ph+, nous avons révélé la persistance sous traitement de cellules BCR::ABL1-positives non leucémiques dans une proportion importante de patients. Cette population cellulaire répondant à la définition d'une hématopoïèse clonale témoignait de la survenue de l'évènement initiateur dans un progéniteur multipotent, remettant en question un dogme en rapprochant la LAL Ph+ de novo de la crise blastique de leucémie myéloïde chronique. Nous avons de plus montré que la maladie résiduelle mesurée sur la fusion BCR::ABL1 n'avait pas d'impact pronostique, contrairement à la réponse évaluée sur des marqueurs spécifiques des lymphoblastes, ceci conduisant à une transformation majeure de la pratique médicale concernant le suivi de la maladie et l'adaptation du traitement. Dans les LAL HoTr, après avoir décrit précisément l'épidémiologie, la composition chromosomique et le paysage mutationnel, nous avons analysé l'architecture clonale à l'aide d'une approche combinée de génotypage et d'immunophénotypage moléculaire à l'échelle unicellulaire. Ceci nous a permis d'identifier la mutation TP53 comme évènement initiateur, à l'origine d'une population pré-leucémique multi-lignée ou hématopoïèse clonale, pouvant persister au cours du traitement de la LAL. Enfin, dans les LAL-B KMT2A-r, nous avons décrit un paysage mutationnel particulièrement pauvre suggérant que le réarrangement de KMT2A peut être suffisant à la transformation oncogénique. L'analyse des réarrangements lymphoïdes suggère de plus que la transformation précède l'engagement lymphoïde. En accord avec ce modèle, nous avons montré que le réarrangement de KMT2A représentait un marqueur de MRD plus pertinent et fiable que les réarrangements lymphoïdes, souvent sous-clonaux. Nous avons également montré que les altérations additionnelles de TP53 et IKZF1 conféraient une plus grande résistance au traitement. L'ensemble nous a permis de proposer une nouvelle stratification du risque tenant compte de l'hétérogénéité biologique et clinique au sein de cette entité. Au total, nos travaux ont permis d'apporter de nouveaux éléments à la compréhension de l'oncogenèse des LAL-B de l'adulte, identifiant la cellule d'origine à un stade multipotent. Dans les LAL Ph+ ou HoTr, nos résultats indiquent que l'évènement initiateur de la leucémie donne naissance à une hématopoïèse clonale pré-leucémique, éclairant le lien observé avec le vieillissement. Ces résultats ont un impact majeur sur les pratiques cliniques quant à l'évaluation de la réponse au traitement, la stratification du risque et les choix thérapeutiques.

  • Open Access

    IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response

    by Sonja Bendig, Alina M. Hartmann, Wiebke Wessels, Thomas Beder, Rathana Kim, Marie Passet, Qingsong Gao, Nadine Wolgast, Johanna M. Horns, Leonardo Alves Santos, et al.

    Large scale sequencing efforts have defined up to 27 diagnostic entities in B-ALL, leaving few samples without subtype assignment. Extended genomic and transcriptomic profiling in routine diagnostics broadens the sample collection and holds the potential to identify novel B-ALL subtypes. By analyzing an aggregated set of 4,857 B-ALL patients from three cohorts, we identified a novel group of twenty cases (age 18-66 years, median: 34 years) characterized by a previously undescribed IGH::FENDRR rearrangement exclusive to this subtype (n=17/20), KRAS p.A146T/V/P mutations (n=17/20 vs. n=86/4,857; p<0.001) and distinct DNA-methylation/gene expression profiles, including overexpression of the lncRNA FENDRR and the transcription factor FOXF1 ('FOXF1/FENDRR') as well as JAK/STAT and RAS signaling signatures. A gene expression machine learning classifier identified FOXF1/FENDRR cases in two independent cohorts with high accuracy. Patients treated according to GMALL/GRAALL protocols showed very poor chemotherapy response with n=8/13 having induction failure or MRD ≥10-3 and n=8/12 remaining MRD positive after 1st consolidation / salvage. MRD-stratified intensification including blinatumomab (n=10) and/or allogenic stem cell transplantation (n=12) resulted in ongoing molecular remission in 13/16 cases. FOXF1/FENDRR patients represent a novel B-ALL subtype which might benefit from early immunotherapeutic treatment or targeted interventions.


  • Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM -Associated Fanconi Anemia

    by Francesco Pegoraro, Lise Larcher, Rathana Kim, Mélanie Pagès, Marie Passet, Aurélie Caye-Eude, Mony Fahd, Benoit Brethon, Lucie Hernandez, Nadia Vasquez, et al.

    PURPOSE: Fanconi anemia (FA) is a genetic disorder typically characterized by progressive bone marrow failure (BMF) during childhood, leading to diagnosis at that stage. In adolescence or adulthood, patients are predisposed to myelodysplastic syndrome (MDS), acute myeloid leukemia, and solid tumors. However, some individuals present atypically, delaying FA recognition and resulting in life-threatening complications. This study describes the distinctive phenotype associated with biallelic FANCM pathogenic variants. PATIENTS AND METHODS: Clinical and biologic data were analyzed from eight patients carrying biallelic germline FANCM pathogenic variants within a French cohort of 411 patients with FA (2.0%). Clinical outcomes were compared with those of patients with FA carrying non- FANCM variants. RESULTS: None of the eight FANCM patients developed BMF, contrasting with a 93.5% cumulative incidence among other FA genotypes ( P < .0001). This absence of marrow failure resulted in delayed FA diagnosis (median age 23.5 v 6.8 years, P < .01). Instead, six patients initially presented with malignancy and exhibited marked toxicity to conventional cancer therapies, prompting FA testing. Malignancies included four oral cancers and, unexpectedly, two ALL: a ZNF384-rearranged B-cell precursor ALL and a BCL11B::HOXA13 early T-cell precursor ALL. No ALL cases occurred among the 403 non- FANCM patients with FA ( P < .0001). The treatment courses of the two FANCM -related ALL cases are reported. CONCLUSION: Biallelic FANCM variants define a distinct FA subtype lacking early BMF, leading to missed diagnoses and severe toxicity upon malignancy. Recognizing this presentation is crucial for timely FA detection and for implementing adapted therapeutic and follow-up strategies.


  • Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia

    by Nicolas Lecornec, Florence Rabian, Marie-Emilie Dourthe, Florian Chevillon, Karima Yakouben, Delphine Chaillou, Sophie Caillat-Zucman, Alexis Cuffel, Emmanuelle Lesprit, Anne Arnould, et al.

    Tisagenlecleucel (tisa-cel), an autologous anti-CD19 CAR T-cell therapy, has significantly improved outcomes in pediatric, adolescents and young adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). However, 30–50% experience early failure or relapse. We retrospectively analyzed 52 cases of early failures (n = 13) or relapses (n = 39), evaluating post-tisa-cel outcomes and prognostic factors. CD19 antigen loss was the only factor associated with a lower complete remission rate after salvage therapy (OR = 0.16, 95%CI [0.03–0.90], p = 0.04). Median overall survival (OS) was 14.5 months, with a 2-year OS of 37.4% (95%CI [24.4–50.4]), similar between early failure (38.5%) and relapse (37.0%) groups (p = 0.78). Patients with measurable residual disease only at salvage initiation had significantly improved 2-year OS (61.9%, (95%CI [38.1–78.8])) compared to those with overt disease (20.7%, (95%CI [8.4–36.7], p = 0.008)). Factors associated with inferior OS included high pre-infusion tumor burden (HR = 3.57, p < 0.01), and prior inotuzumab ozogamicin exposure (HR = 3.81, p < 0.01). Although salvage therapies and hematopoietic stem cell transplantation benefit some patients, 5 of 18 transplanted patients died from treatment-related toxicity, underscoring the significant associated risks. These findings highlight the poor prognosis of tisa-cel failures and the urgent need for novel strategies.

  • Open Access

    In vivo isogenic modelling unveils TP53 -associated relapse trajectories in T-cell acute lymphoblastic leukemia

    by Stéphanie Gachet, Samuel Quentin, Lucie Hernandez, Loïc Maillard, Marie Passet, Rathana Kim, Hugo Bergugnat, Melha Benlebna, Rémy Jelin, Marine Aglave, et al.

    Many patients with T-cell acute lymphoblastic leukemia (T-ALL) relapse into a treatment-resistant disease. The mechanisms driving relapse remain largely elusive, in part due to the lack of faithful experimental models. Here, we leveraged patient-derived xenograft (PDX) pairs generated from diagnosis and relapse T-ALLs to functionally address the cellular mechanisms driving TP53- altered relapse. Beyond inter-T-ALL variability, comparative analyses revealed a unique, cell-intrinsic relapse phenotype that includes greater leukemia-initiating capacity and that can be conferred to diagnosis cells by TP53 silencing. Transcriptomic profiling linked the relapse phenotype to deregulated OXPHOS metabolism and MYC signaling. Integration of single-cell profilings uncovered TP53- wildtype cell populations at diagnosis expressing a relapse profile, possibly reflecting a pre-existing modulation of TP53 signaling. These cells sequentially evolved towards biallelic TP53 inactivation at relapse. Collectively, our findings support a model in which T-ALL relapses emerge from a selected pre-existing transcriptional state characterized by deregulated metabolism that favors subsequent TP53 inactivation.